The extension of the exclusive distribution agreement for KetoAir positions Avalon GloboCare in a unique spot within the health and wellness sector, particularly in the growing markets of diabetes and obesity management. The innovative nature of the KetoAir device, being the first AI-enabled breathalyzer for ketogenic health, along with the planned launches, could significantly enhance Avalon's market presence and potentially its stock value in the short term. The focus on a health-conscious consumer base and the strategic targeting of prevalent health issues like diabetes and obesity underscore the potential for increased demand and visibility for Avalon's offerings.